Burden Of Alzheimer’s Disease On Patients & Caregivers

Clinical and Humanistic Burden Associated With Alzheimer’s Disease In The United States: 
An Analysis Of Patient Characteristics, Treatment Patterns, And Quality Of Life Using A Physician Notes Real-World Database 

This poster was originally presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference 2024, held May 5–June 8, 2024, in Atlanta, GA. 

Authors: David Iwanyckyj, Pablo Racana, Ashley Gamble, PhD, Melanie Jardim, PhD 

Affiliations: Amplity, Langhorne, PA, USA 

Introduction  

This study leveraged AnswerY™ (formerly known as Amplity Insights), our robust, HIPAA-compliant real-world database (RWD), composed of transcribed physician notes, to characterize the real-world clinical and humanistic burden of Alzheimer’s disease (AD).  

Methods  

• >60 million electronic medical transcription records from the AnswerY RWD were analyzed from nearly 120,000 healthcare providers at ~40,000 inpatient/outpatient care sites across 50 states and 2 U.S. territories. 
• Patient-level characteristics, comorbidities, symptoms, quality of life (QoL), testing, and treatment usage were summarized and described for the following 4 cohorts: All patients, patients aged 50-64 years, patients aged 65-79 years, and patients aged ≥80 years. 

Results 

• The path to AD diagnosis can be long, and patients with AD experience psychological symptoms years in advance of diagnosis and continue to experience those symptoms at higher rates post-diagnosis than cognitive impairment and confusion symptoms. 

• Disease symptoms significantly impact patients and carry a significant QoL burden, which extends to their caregivers. 

• Diagnostic and treatment decisions remain focused on clinical symptoms versus a biomarker-guided approach. 

Conclusions  

• Analysis of this RWD revealed the pattern of symptoms and comorbidities experienced by patients with AD, which impacts QoL and creates a burden that extends to their caregivers.  
• Use of these data can help identify barriers to patients accessing biomarker evaluation in AD and opportunities to improve the quality of care in different patient populations.

DOWNLOAD POSTER